Caris Life Sciences (CAI) Cash from Investing Activities (2024 - 2026)

Caris Life Sciences' Cash from Investing Activities history runs 3 years deep, the most recent figure standing at -$10.3 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 284.6% year-over-year to -$10.3 million; the TTM figure through Mar 2026 stood at -$23.9 million (changed N/A YoY), while the FY2025 annual figure was -$16.3 million, down 130.72% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$10.3 million, down from -$5.1 million in the prior quarter.
• The five-year high for Cash from Investing Activities was -$1.4 million in Q2 2025, with the low at -$10.3 million in Q1 2026.
• The 3-year median for Cash from Investing Activities is -$2.7 million (2025), against an average of -$4.4 million.
• Peak annual rise in Cash from Investing Activities reached 122.27% in 2025, while the deepest fall reached 288.13% in 2025.
• Caris Life Sciences' Cash from Investing Activities stood at -$2.3 million in 2024, then sank by 122.27% to -$5.1 million in 2025, then sank by 103.18% to -$10.3 million in 2026.
• Business Quant data shows CAI's Cash from Investing Activities at -$10.3 million in Q1 2026, -$5.1 million in Q4 2025, and -$7.1 million in Q3 2025.